Prognostic significance of p53 immunostaining in epithelial ovarian cancer

Journal of Clinical Oncology

Volumn 12, Issue 1, 1994, Pages 64-69

  Hartmann, Lynn C ^a   Podratz, Karl C ^a   Keeney, Gary L ^a   Kamel, Nermeen A ^a   Edmonson, John H ^a   Grill, Joseph P ^a   Su, John Q ^a   Katzmann, Jerry A ^a   Roche, Patrick C ^a  

^a MAYO CLINIC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BIOLOGICAL MARKER; PROTEIN P53;

ADULT; AGED; ARTICLE; CANCER GRADING; CANCER STAGING; CANCER SURVIVAL; CLINICAL TRIAL; CORRELATION FUNCTION; FEMALE; GENE EXPRESSION; HUMAN; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; OVARY CARCINOMA; PRIORITY JOURNAL;

EID: 0028009626     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.1994.12.1.64     Document Type: Article

References (23)

1. Henderson BE, Ross RK, Pike MC: Toward the primary prevention of cancer. Science 254:1131-1138, 1991
2. Kacinski BM, Chambers SK: Molecular biology of ovarian cancer. Curr Opin Oncol 3:889-900, 1991
3. Levine A: The p53 tumour suppressor gene and product, in Cancer Surveys, Volume 12: Tumour Suppressor Genes, the Cell Cycle and Cancer. Imperial Cancer Research Fund. Oxford, England, Oxford University Press, 1992, pp 59-79
4. Vogelstein B, Kinzler KW: p53 function and dysfunction. Cell 70:523-526, 1992
5. Hupp TR, Meek EW, Midgley CA, et al: Regulation of the specific DNA binding function of p53. Cell 71:875-886, 1992
6. Livingstone LR, White A, Sprouse J, et al: Altered cell cycle arrest and gene amplification potential accompany loss of wild-type p53. Cell 70:923-935, 1992
7. Nigro JM, Baker SJ, Preisinger CA, et al: Mutations in the p53 gene occur in diverse human tumour types. Nature 342:705-708, 1989
8. Gannon JV, Greaves R, Iggo R, et al: Activating mutations in p53 produce a common conformational effect. A monoclonal antibody specific for the mutant form. EMBO J 9:1595-1602, 1990
9. Kihana T, Tsuda H, Teshima S, et al: High incidence of p53 gene mutation in human ovarian cancer and its association with nuclear accumulation of p53 protein and tumor DNA aneuploidy. Jpn J Cancer Res 83:978-984, 1992
10. Marks JR, Davidoff AM, Kerns BJ, et al: Overexpression and mutation of p53 in epithelial ovarian cancer. Cancer Res 51:2979-2984, 1991
11. Okamoto A, Sameshima Y, Yokoyama S, et al: Frequent allelic losses and mutations of the p53 gene in human ovarian cancer. Cancer Res 51:5171-5176, 1991
12. Eccles DM, Brett L, Lessells A, et al: Overexpression of the p53 protein and allele loss at 17p13 in ovarian carcinoma. Br J Cancer 65:40-44, 1992
13. Cancer Committee of the International Federation of Gynecology and Obstetrics: Staging Announcement: FIGO Cancer Committee. Gynecol Oncol 25:383-385, 1986
14. Hedley DW, Friedlander ML, Taylor IW, et al: Method for analysis of cellular DNA content of paraffin-embedded pathologic material using flow cytometry. J Histochem Cytochem 31:1333-1335, 1983
15. Vindelov LL, Christensen IJ, Nissen NI: A detergent-trypsin method for the preparation of nuclei for flow cytometric DNA analysis. Cytometry 3:323-327, 1983
16. Baisch H, Gohde W, Linden WA: Analysis of PCP-data to determine the fraction of cells in the various phases of cell cycle. Radiat Environ Biophys 12:31-39, 1975
17. Kaplan E, Meier P: Nonparametric estimation for incomplete observations. J Am Stat Assn 53:457-481, 1958
18. Mantel N: Evaluation of survival data and two new rank order statistics arising in its consideration. Cancer Chemother Rep 50:163-170, 1966
19. Cox DR: Regression models and life tables. J R Stat Soc 34:187-220, 1972
20. Levine AJ, Momand J, Finlay CA: The p53 tumor suppressor gene. Nature 351:453-456, 1991
21. Hollstein M, Sidransky D, Vogelstein B, et al: p53 mutations in human cancers. Science 253:49-53, 1991
22. Donehower LA, Harvey M, Slagle BL, et al: Mice deficient for p53 are developmentally normal but susceptible to spontaneous tumours. Nature 356:215-221, 1992
23. Tishler RB, Calderwood SK, Coleman CN: Increases in sequence specific DNA binding by p53 following treatment with chemotherapeutic and DNA damaging agents. Cancer Res 53:2212-2216, 1993